IL17A and neoplasm: To understand the effects of colitis-related IL-17A on reducing CD8+ T cell numbers in the tumor bed, we transferred the activated OT-I cells from CD45.2 mice (donor) into B16-OVA-bearing CD45.1 mice (recipient) and treated the mice as did in Fig. 1F. The numbers of donor-derived CD8+ T cells (CD45.2+) in the tumors of colitis mice reduced more significantly (Fig. 2C).